ArticleScientific reports2016
CdGAP/ARHGAP31, a Cdc42/Rac1 GTPase regulator, is critical for vascular development and VEGF-mediated angiogenesis.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Sex-specific autosomal susceptibility loci in systemic sclerosis: a genome-wide association study.The Lancet. Rheumatology · 2026Pooled it
- Identification of a novel genetic locus associated with immune-mediated thrombotic thrombocytopenic purpura.Haematologica · 2022Pooled it
- Decoding the senescent endothelial landscape in ischemic stroke through single-cell and bulk RNA sequencing.Functional & integrative genomics · 2026Article
- Serum exosomal miR-192-5p as a novel predictive biomarker for immunochemotherapy response in advanced non-small cell lung cancer.BMC cancer · 2026Article
- Identifying selection signatures associated with production traits in Matou goats using whole-genome sequencing.Journal of animal science · 2026Article
- Rabenosyn-5 suppresses non-small cell lung cancer metastasis via inhibiting CDC42 activity.Cancer gene therapy · 2024Article
- Comprehensive analysis of circRNA-miRNA-mRNA network related to angiogenesis in recurrent implantation failure.BMC medical genomics · 2024Article
- Characterization of a New Variant inGenes · 2024Article
- A DLG1-ARHGAP31-CDC42 axis is essential for the intestinal stem cell response to fluctuating niche Wnt signaling.Cell stem cell · 2023Article
- CdGAP maintains podocyte function and modulates focal adhesions in a Src kinase-dependent manner.Scientific reports · 2022Article
- Synergistic effects of rare variants of ARHGAP31 and FBLN1Frontiers in genetics · 2022Article
- CdGAP promotes prostate cancer metastasis by regulating epithelial-to-mesenchymal transition, cell cycle progression, and apoptosis.Communications biology · 2021Article
- The DOCK protein family in vascular development and disease.Angiogenesis · 2021Review
- Identification of diverse tumor endothelial cell populations in malignant glioma.Neuro-oncology · 2021Article
- Weighted Single-Step Genome-Wide Association Study for Growth Traits in Chinese Simmental Beef Cattle.Genes · 2020Article
- CD226 deletion improves post-infarction healing via modulating macrophage polarization in mice.Theranostics · 2020Article
- Cytosine methylation predicts renal function decline in American Indians.Kidney international · 2018Article
- CdGAP/ARHGAP31 is regulated by RSK phosphorylation and binding to 14-3-3β adaptor protein.Oncotarget · 2018Article
- The scaffold protein Ajuba suppresses CdGAP activity in epithelia to maintain stable cell-cell contacts.Scientific reports · 2017Article
- The Cdc42/Rac1 regulator CdGAP is a novel E-cadherin transcriptional co-repressor with Zeb2 in breast cancer.Oncogene · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
Mutations in the CdGAP/ARHGAP31 gene, which encodes a GTPase-activating protein for Rac1 and Cdc42, have been reported causative in the Adams-Oliver developmental syndrome often associated with vascular defects. However, despite its abundant expression in endothelial cells, CdGAP function in the vasculature remains unknown. Here, we show that vascular development is impaired in CdGAP-deficient mouse embryos at E15.5. This is associated with superficial vessel defects and subcutaneous edema, resulting in 44% embryonic/perinatal lethality. VEGF-driven angiogenesis is defective in CdGAP(-/-) mice, showing reduced capillary sprouting from aortic ring explants. Similarly, VEGF-dependent endothelial cell migration and capillary formation are inhibited upon CdGAP knockdown. Mechanistically, CdGAP associates with VEGF receptor-2 and controls VEGF-dependent signaling. Consequently, CdGAP depletion results in impaired VEGF-mediated Rac1 activation and reduced phosphorylation of critical intracellular mediators including Gab1, Akt, PLCγ and SHP2. These findings are the first to demonstrate the importance of CdGAP in embryonic vascular development and VEGF-induced signaling, and highlight CdGAP as a potential therapeutic target to treat pathological angiogenesis and vascular dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.